CJC-1295 / Ipamorelin

Overview

The CJC-1295 / Ipamorelin combination is one of the most-studied research protocols in the GH-axis peptide literature. It pairs two distinct mechanisms: a long-acting GHRH analogue (CJC-1295) that signals the pituitary to release growth hormone, and a selective ghrelin/growth-hormone-secretagogue-receptor (GHS-R) agonist (Ipamorelin) that operates on a parallel but synergistic pathway.

CJC-1295 itself was developed by ConjuChem in the early 2000s as a modified GHRH 1-29 analogue with amino-acid substitutions at positions 2, 8, 15 and 27 that confer resistance to dipeptidyl-peptidase IV degradation. The compound exists in two forms: CJC-1295 without DAC (essentially a stabilised short-acting GHRH analogue with ~30-minute half-life) and CJC-1295 with DAC (Drug Affinity Complex modification — a maleimidopropionic acid linker that covalently binds circulating albumin and extends the half-life to 6–8 days).

Ipamorelin was developed by Novo Nordisk in the late 1990s as a selective GHS-R agonist with minimal effect on prolactin, ACTH or cortisol release — distinguishing it from earlier-generation GHRPs (GHRP-2, GHRP-6) which produced broader off-target hormonal effects. The selectivity profile is the principal reason Ipamorelin is preferred over those earlier compounds in research protocols.

Used together, CJC-1295 (GHRH signal) and Ipamorelin (GHS-R signal) act through complementary pituitary receptors, producing GH release that exceeds the sum of either agent alone while preserving the negative feedback regulation that keeps IGF-1 elevation within physiological bounds.

Mechanism of action

CJC-1295 acts through the GHRH receptor on anterior pituitary somatotrophs, the same target as sermorelin and endogenous GHRH. The stabilising substitutions extend half-life dramatically — particularly with DAC modification, where covalent albumin binding produces a circulating depot lasting several days. Without DAC, CJC-1295 produces brief enhanced pulsatile release; with DAC, GH-pulse frequency and amplitude are elevated continuously.

Ipamorelin acts through the GHS-R1a receptor — the ghrelin receptor — on the same somatotrophs and on hypothalamic neurons. GHS-R activation triggers phospholipase-C-mediated calcium signalling and complements the cAMP-mediated GHRH response. The two pathways converge to produce GH release with characteristics neither agent produces alone.

Because GHS-R is also expressed on hypothalamic neurons regulating somatostatin tone, Ipamorelin transiently reduces somatostatin inhibition of pituitary GH release — effectively releasing the somatostatin 'brake' while CJC-1295 pushes the GHRH 'accelerator'. This combined action is the mechanistic basis for the synergistic effect observed when the two compounds are administered together.

Critically, the combination preserves the IGF-1 negative-feedback loop. Sustained elevation of IGF-1 reduces hypothalamic GHRH output and increases somatostatin tone, limiting the pituitary response. This contrasts with recombinant GH supplementation, where no such feedback operates and supraphysiological IGF-1 can be sustained indefinitely.

Research history

CJC-1295 was developed by ConjuChem in the early 2000s. Phase I clinical trials in 2005–2006 demonstrated dose-dependent IGF-1 elevation with the DAC-modified form lasting up to 11 days after single administration. Commercial development was discontinued, and CJC-1295 has remained primarily a research compound rather than a licensed medicine.

Ipamorelin was developed by Novo Nordisk in the late 1990s. It progressed into early-phase clinical trials, with subsequent development by Helsinn focusing on post-operative ileus and other gastrointestinal indications — different applications from the GH-stimulation context. As of the most recent regulatory cycle, Ipamorelin does not hold broad marketing authorisation.

The combination protocol — CJC-1295 + Ipamorelin — emerged from research and off-label use through the 2010s as a peptide-research analogue of the body's natural GHRH/ghrelin signalling. It has become the canonical 'longevity-context' GH-axis protocol in research-peptide literature, although large-scale clinical evidence specifically on this combination remains limited.

Summarised studies